Phase I/II study of tecemotide cancer immunotherapy for Japanese patients with unresectable stage III non-small cell lung cancer (NSCLC).

被引：3
作者：
Nokihara, Hiroshi
Katakami, Nobuyuki
Hida, Toyoaki
Imamura, Fumio
Sakai, Hiroshi
Atagi, Shinji
Nishio, Makoto
Helwig, Christoph
Achiwa, Hiroyuki
Tamura, Tomohide
机构：
[1] Natl Canc Ctr, Tokyo, Japan
[2] Inst Biomed Res & Innovat, Kobe, Hyogo, Japan
[3] Aichi Canc Ctr Hosp, Dept Thorac Oncol, Nagoya, Aichi 464, Japan
[4] Osaka Med Ctr, Osaka, Japan
[5] Saitama Canc Ctr, Saitama, Japan
[6] Kinki Chuo Chest Med Ctr, Osaka, Japan
[7] Japanese Fdn Canc Res, Tokyo, Japan
[8] Merck KGaA, Darmstadt, Germany
[9] Merck Serono Co Ltd, Tokyo, Japan
[10] St Lukes Int Hosp, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.3036
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3036
引用
收藏
页数：1
相关论文
共 50 条
[41]   Phase I/II study of exisulind and gemcitabine in patients with recurrent advanced non-small cell lung cancer (NSCLC). [J].
Hoang, T ;
Kim, K ;
Merchant, J ;
Traynor, AM ;
Ahuja, HG ;
Masters, GA ;
McGovern, JD ;
Oettel, KR ;
Sanchez, FA ;
Schiller, JH .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) :642S-642S
[42]   Phase I/II study of weekly docetaxel in patients with previously treated non-small cell lung cancer (NSCLC). [J].
Hirata, T ;
Kawashita, F ;
Ogawa, E ;
Masago, K ;
Kato, M ;
Takada, M .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) :676S-676S
[43]   A phase II nonrandomized trial of sequential chemoradiation (gemcitabine/carboplatin plus thoracic irradiation) in patients with unresectable stage III non-small cell lung cancer (NSCLC). [J].
Hamada, E .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) :679S-679S
[44]   Phase I/II study of stage III and IV non-small cell lung cancer patients taking a specific dietary supplement [J].
Sun, AS ;
Ostadal, O ;
Ryznar, V ;
Dulik, I ;
Dusek, J ;
Vaclavik, A ;
Yeh, HC ;
Hsu, C ;
Bruckner, HW ;
Fasy, TM .
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 1999, 34 (01) :62-69
[45]   Consolidation of immunotherapy becomes new standard of care in unresectable stage III non-small cell lung cancer [J].
Ahn, Myung-Ju .
JOURNAL OF THORACIC DISEASE, 2018, 10 (03) :1205-1206
[46]   Phase II Study of Cisplatin with Irinotecan as Induction Chemotherapy Followed by Chemoradiotherapy for Unresectable Stage III Non-small Cell Lung Cancer [J].
Chang, Hyun ;
Kim, Se Hyun ;
Cho, Byoung Chul ;
Yoon, Sang Hyun ;
Kim, Hye Ryun ;
Lee, Chang Geol ;
Kim, Joo Hang .
ANTICANCER RESEARCH, 2012, 32 (08) :3515-3521
[47]   Phase i study of cisplatin analogue nedaplatin, paclitaxel, and thoracic radiotherapy for unresectable stage III non-small cell lung cancer [J].
Sekine, Ikuo ;
Sumi, Minako ;
Ito, Yoshinori ;
Kato, Terufumi ;
Fujisaka, Yasuhito ;
Nokihara, Hiroshi ;
Yamamoto, Noboru ;
Kunitoh, Hideo ;
Ohe, Yuichiro ;
Tamura, Tomohide .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2007, 37 (03) :175-180
[48]   Phase II Study of Erlotinib in Japanese Patients with Advanced Non-small Cell Lung Cancer [J].
Takahashi, Toshiaki ;
Yamamoto, Nobuyuki ;
Nukiwa, Toshihiro ;
Mori, Kiyoshi ;
Tsuboi, Masahiro ;
Horai, Takeshi ;
Masuda, Noriyuki ;
Eguchi, Kenji ;
Mitsudomi, Tetsuya ;
Yokota, Soichiro ;
Segawa, Yoshihiko ;
Ichinose, Yukito ;
Fukuoka, Masahiro ;
Saijo, Nagahiro .
ANTICANCER RESEARCH, 2010, 30 (02) :557-563
[49]   A phase II study of concurrent pemetrexed/cisplatin/radiation (RT) for unresectable stage IIIA/b non-small cell lung cancer (NSCLC) [J].
Brade, A. M. ;
Bezjak, A. ;
MacRae, R. M. ;
Laurie, S. A. ;
Wang, L. ;
Capobianco, S. ;
Shepherd, F. A. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[50]   Phase II pilot study of neoadjuvant docetaxel and cisplatin followed by adjuvant erlotinib in patients with stage I-III non-small cell lung cancer (NSCLC) [J].
Gold, K. A. ;
Lee, J. J. ;
Rice, D. ;
Tse, W. ;
Stewart, D. ;
Wistuba, I. ;
Herbst, R. S. ;
Lippman, S. M. ;
Hong, W. K. ;
Kim, E. S. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345